Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

https://ift.tt/5dIMsiG

 

from Sanofi - Aventis Groupe https://ift.tt/QKG45mV
via IFTTT